Marshall Wace’s AYTU BioPharma AYTU Stock Holding History

Marshall Wace’s Portfolio AYTU Stock Details AYTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-2,600	Closed	-$70K	–	3347
2021 Q4	$70K	Buy	+2,600	New	+$112K	﹤0.01%	3477

Other funds holding AYTU

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Marshall Wace's AYTU Position: Q1 2022 in Review

Marshall Wace sold out of AYTU BioPharma (AYTU) in Q1 2022, closing a stake of 2,600 shares — an estimated $70K sold.

Marshall Wace first reported a position in AYTU in Q4 2021 and held it in 1 quarter. The position peaked at $70K in Q4 2021. 32 funds tracked by Wall St. Rank hold AYTU as of Q1 2022.

Marshall Wace reported no remaining AYTU BioPharma position as of Q1 2022 after selling out during the quarter.
Marshall Wace sold 2,600 AYTU BioPharma shares in Q1 2022, an estimated $70K.
Marshall Wace first reported a position in AYTU BioPharma in Q4 2021 and held it in 1 quarter.
Marshall Wace's AYTU BioPharma position peaked at $70K in Q4 2021.
32 funds tracked by Wall St. Rank held AYTU BioPharma as of Q1 2022.

Based on Marshall Wace's 13F filing for Q1 2022, filed 16 May 2022.